Opus Genetics, Inc. Form 4 Filings

Opus Genetics, Inc. (IRD) reported that Chief Executive Officer and director George Magrath exercised a warrant for 392,157 shares of Common Stock on September 9, 2026 at an exercise price of $1.15 per share. The exercise was completed on a cashless basis, with 75,541 shares withheld to pay the exercise price and 316,616 shares issued to him. The warrant, which was immediately exercisable upon acquisition on March 24, 2025 and subject to specified stock-price and trading-volume call conditions, now shows no remaining derivative position in this filing.

Opus Genetics, Inc. (IRD) director Cam Gallagher exercised a warrant to acquire 784,314 shares of common stock on September 8, 2026 at an exercise price of $1.15 per share, converting a warrant that is now reported with zero remaining underlying shares.

Following this exercise, Gallagher directly holds 2,800,111 shares of common stock and also has an indirect position of 83,000 shares held as custodian for a minor under the Uniform Transfers to Minors Act, for which beneficial ownership is disclaimed except for any pecuniary interest. In connection with the warrant exercise, Gallagher entered into a Lock-Up Agreement dated September 6, 2026, agreeing not to transfer or dispose of common stock or related securities for 180 days after issuance of the exercised shares, subject to exclusions and with the issuer’s written consent requirement.

Opus Genetics, Inc. (IRD) reported that its Chief Financial Officer, Robert E. Gagnon, sold 28,000 shares of common stock on September 3, 2026. The weighted average sale price was $4.5433 per share, in multiple trades between $4.29 and $4.79, leaving him with 556,375 shares held directly. A portion of the shares was sold automatically to cover tax withholding from vesting restricted stock units, and the remainder was sold under a pre-arranged Rule 10b5-1 trading plan adopted on April 30, 2026.

Opus Genetics, Inc. director and President Benjamin R. Yerxa reported an automatic sale of 7,429 shares of Common Stock on July 23, 2026 at $2.97 per share. The shares were automatically sold on his behalf, as required by the company, to satisfy tax withholding from a restricted stock unit vesting and settlement event, and the sale is described as not representing a discretionary trade. After this transaction, he directly holds 704,106 shares of Common Stock.

Opus Genetics, Inc. reported that its Chief Operating Officer, Joseph K. Schachle, had 4,644 shares of common stock sold on July 23, 2026 at $2.94 per share. The shares were sold automatically to satisfy tax withholding obligations from a restricted stock unit vesting and were not a discretionary trade. Following this transaction, Schachle directly held 291,440 shares of Opus Genetics common stock.

Opus Genetics, Inc. Chief Executive Officer George Magrath reported an automatic sale of 9,475 shares of common stock on July 23, 2026 to satisfy tax withholding obligations arising from a restricted stock unit vesting. The shares were sold at a weighted average price of $2.9473, within a $2.9009–$3.025 range, leaving 1,731,869 directly held shares after the transaction. The sale did not represent a discretionary trade by the reporting person, and the Rule 10b5‑1 trading plan checkbox for the filing was not selected.

Opus Genetics, Inc. Chief Financial Officer Robert E. Gagnon reported an automatic sale of 7,783 shares of common stock on July 23, 2026 at a weighted average price of $2.9477 per share, in multiple trades between $2.9006 and $3.025, to satisfy tax withholding from a restricted stock unit vesting. Following this sale, he directly holds 584,375 shares.

Opus Genetics, Inc. director entities Foundation Fighting Blindness Retinal Degeneration Fund and Foundation Fighting Blindness, Inc. reported an open-market sale of 1,700,000 shares of Common Stock of Opus Genetics at $4.35 per share.

The shares are owned directly by Foundation Fighting Blindness Retinal Degeneration Fund, whose board controls voting and investment decisions, while Foundation Fighting Blindness, Inc. is its sole member and may be deemed to beneficially own these securities. After the transaction, the reporting entities continue to hold 3,792,171 shares of Opus Genetics common stock.

Opus Genetics, Inc. director and President Benjamin R. Yerxa reported an open-market sale of 7,470 shares of common stock at a weighted average price of $5.2371 per share. The shares were sold automatically by the company to satisfy tax withholding obligations from a restricted stock unit vesting event and were not a discretionary trade. After this transaction, Yerxa holds 711,535 shares of Opus Genetics common stock directly.

Opus Genetics, Inc. Chief Operating Officer Joseph K. Schachle reported an automatic share sale tied to tax withholding. On this transaction, 4,697 shares of common stock were sold at $5.2202 per share to satisfy tax obligations arising from a restricted stock unit vesting and settlement event. The filing notes this was not a discretionary trade by the executive. After the sale, Schachle directly holds 296,084 shares of Opus Genetics common stock.

Opus Genetics, Inc. executive Amy Zaremba Rabourn reported an automatic sale of 1,641 shares of common stock at a weighted average price of $5.204 per share. The company executed the sale to cover tax withholding obligations from a restricted stock unit vesting event.

This was not a discretionary trade by the officer. After the sale, she still directly holds 188,671 shares, so the transaction represents a small portion of her total reported holdings.

Opus Genetics, Inc. Chief Executive Officer George Magrath reported an automatic disposition of common stock tied to a tax event. On April 23, 2026, 9,511 shares of common stock were sold at $5.22 per share to satisfy tax withholding obligations from a restricted stock unit vesting and settlement. According to the filing, this did not represent a discretionary trade by the executive. After this transaction, Magrath directly holds 1,741,344 shares of Opus Genetics common stock.

Opus Genetics, Inc. Chief Scientific & Dev. Officer Jayagopal Ashwath reported an automatic sale of common stock tied to tax obligations. On this Form 4, 7,542 shares were sold in an open-market transaction at a weighted average price of $5.1917 per share.

According to the footnotes, the sale was executed automatically by the company to satisfy tax withholding arising from a restricted stock unit vesting and settlement, and was not a discretionary trade. After the sale, Ashwath directly owns 509,233 shares of Opus Genetics common stock.

Opus Genetics, Inc. Chief Financial Officer Robert E. Gagnon reported an automatic sale of 7,842 shares of Common Stock on April 23, 2026. The sale was executed at a weighted average price of $5.1846 per share to satisfy tax withholding obligations arising from the vesting and settlement of a restricted stock unit award, and was not a discretionary trade. After this transaction, Gagnon directly holds 592,158 shares of Opus Genetics common stock. The shares were sold in multiple trades at prices ranging from $5.1828 to $5.1901 per share.

Rodgers Richard J reported acquisition or exercise transactions in this Form 4 filing.

Opus Genetics, Inc. director Richard J. Rodgers received an equity grant in the form of restricted stock units covering 24,367 shares of common stock. The award was granted at no cash cost per share and is part of his director compensation.

The restricted stock units vest upon the earlier of the one-year anniversary of the grant date or the day before Opus Genetics’ next annual stockholders’ meeting, provided he continues to serve through the vesting date. After this grant, he directly holds 343,022 shares of common stock.

MANUSO JAMES S J reported acquisition or exercise transactions in this Form 4 filing.

Opus Genetics, Inc. director JAMES S J MANUSO received a grant of 24,367 shares of Common Stock in the form of restricted stock units at a stated price of $0.00 per share. Following this award, he holds 317,318 shares directly. The RSUs vest upon the earlier of one year from the grant date or the day before the company’s next annual meeting of stockholders, provided he continues in service through the vesting date.

Graves Adrienne L reported acquisition or exercise transactions in this Form 4 filing.

Opus Genetics, Inc. director Adrienne L. Graves received a grant of 24,367 shares of Common Stock in the form of restricted stock units as compensation. These units vest upon the earlier of one year from the grant date or the day before the company’s next annual stockholder meeting, subject to continued service. After this award, Graves directly holds 127,514 shares of common stock.

Gallagher Cam reported acquisition or exercise transactions in this Form 4 filing.

Opus Genetics, Inc. director Cam Gallagher reported an equity compensation grant and updated share holdings. He received 24,367 shares of Common Stock as a grant of restricted stock units at $0.0000 per share, which vest upon the earlier of one year from grant or the day before the next annual stockholder meeting, subject to continued service. Following this grant, he directly holds 2,015,797 Common Stock shares. A separate holding entry shows 83,000 Common Stock shares held indirectly as custodian for a minor child under the Uniform Transfer to Minors Act, for which he disclaims beneficial ownership except to any pecuniary interest.

Benton Susan reported acquisition or exercise transactions in this Form 4 filing.

Opus Genetics, Inc. director Susan Benton received a grant of 24,367 restricted stock units of common stock as equity compensation. The units vest on the earlier of one year from the grant date or the day before the company’s next annual stockholder meeting, contingent on her continued service. After this grant, she directly holds 243,894 shares of common stock.

Opus Genetics, Inc. director Jean Bennett received a grant of 24,367 shares of Common Stock in the form of restricted stock units on April 20, 2026. The grant has no cash exercise price and represents equity compensation rather than an open-market purchase.

The restricted stock units vest upon the earlier of the one-year anniversary of the grant date or the day prior to Opus Genetics’ next annual meeting of stockholders, as long as Bennett continues in service through the vesting date. Following this grant, her direct holdings increased to 259,019 shares of Common Stock.

Ainsworth Sean reported acquisition or exercise transactions in this Form 4 filing.

Opus Genetics, Inc. director Sean Ainsworth received an equity grant in the form of restricted stock units. The award covers 24,367 units of common stock at no cash cost, reflecting compensation rather than an open-market purchase.

The restricted stock units vest upon the earlier of the one-year anniversary of the grant date or the day before Opus Genetics’ next annual meeting of stockholders, assuming Ainsworth continues in service through that date. Following this grant, he holds 321,692 shares of common stock directly.

Opus Genetics, Inc. Chief Operating Officer Joseph K. Schachle reported an automatic sale of 3,719 shares of common stock at $5.2501 per share. The company executed this sale to satisfy tax withholding obligations arising from a restricted stock unit vesting event, and it was not a discretionary trade by Schachle. After the transaction, he directly holds 300,781 shares of Opus Genetics common stock.

Opus Genetics, Inc. executive Amy Zaremba Rabourn, Head of Financial Quality Assurance, reported an automatic sale of 2,816 shares of common stock at $5.245 per share. The shares were sold by the company to satisfy tax withholding obligations from a restricted stock unit vesting event, and the filing states this was not a discretionary trade. After this transaction, she directly holds 190,312 shares of common stock.

Opus Genetics, Inc. Chief Executive Officer George Magrath reported an automatic sale of 24,438 shares of common stock at a weighted average price of $5.2102 per share. The shares were sold by the company to cover tax withholding obligations arising from a restricted stock unit vesting event and were not a discretionary trade by the executive. Following this tax-related transaction, Magrath directly holds 1,750,855 shares of Opus Genetics common stock.

Opus Genetics, Inc. Chief Scientific & Dev. Officer Jayagopal Ashwath reported an automatic sale of 3,719 shares of common stock at a weighted average price of $5.1213 per share. The shares were sold to cover tax withholding obligations from a restricted stock unit vesting event and were not a discretionary trade. After this transaction, he holds 516,775 shares directly.

Jayagopal Ashwath reported disposition transactions in a Form 4 filing for IRD. The filing lists transactions totaling 5,313 shares at a weighted average price of $3.39 per share. Following the reported transactions, holdings were 520,494 shares.

Opus Genetics, Inc. President and director Benjamin R. Yerxa reported an equity award in the form of 400,000 shares of common stock on January 22, 2026. The filing shows the shares at a price of $0 per share, reflecting a grant rather than an open-market purchase. Following this transaction, he beneficially owns 719,005 shares of common stock directly. According to the footnote, the award represents restricted stock units that vest in substantially equal quarterly installments on each anniversary of the grant date over the next sixteen quarters, conditioned on his continued service.

Opus Genetics, Inc. reported that its Chief Operating Officer, Joseph K. Schachle, received a grant of 250,000 shares of common stock in the form of restricted stock units on 01/22/2026. These RSUs vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen quarters, conditioned on his continuing service with the company. The grant was recorded at a price of $0 per share, reflecting that no cash payment is required from him for the award. Following this transaction, he beneficially owns 304,500 shares of Opus Genetics common stock, held directly.

Opus Genetics, Inc. granted 86,500 shares of its common stock in the form of restricted stock units to executive Amy Zaremba Rabourn, who serves as Head of Fin. Quality Assurance. The grant was made on January 22, 2026 at a price of $0 per share, reflecting an equity award rather than a market purchase.

The restricted stock units vest in substantially equal quarterly installments on each anniversary of the grant date over the next sixteen quarters, as long as she continues in service. After this grant, she beneficially owns 193,128 shares of common stock directly.

Opus Genetics, Inc. Chief Executive Officer and director Magrath George reported an equity award of company common stock. On January 22, 2026, he received 483,639 shares of common stock at a price of $0 per share, described as a grant of restricted stock units. After this grant, he beneficially owned 1,775,293 shares of Opus Genetics common stock in direct ownership.

The restricted stock units vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen quarters, and vesting is conditioned on his continuing service.

Opus Genetics, Inc. reported an equity award to its Chief Scientific & Dev. Officer, Jayagopal Ashwath. On January 22, 2026, he received 400,000 shares of common stock at a price of $0 per share, reported as a grant of restricted stock units. These RSUs vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen quarters, as long as he continues in service. Following this grant, he beneficially owns 525,807 shares of Opus Genetics common stock directly.

Opus Genetics, Inc. reported an equity award to its Chief Financial Officer, Robert E. Gagnon. On January 22, 2026, he received 400,000 shares of common stock at a price of $0 per share, reported as an acquisition. A footnote explains that this represents a grant of restricted stock units that vest in substantially equal quarterly installments on the anniversary of the grant date over the next 16 quarters, subject to his continuing service. Following this grant, Gagnon beneficially owned 600,000 shares of Opus Genetics common stock, held directly.

Opus Genetics, Inc. officer Amy Zaremba Rabourn, Head of Financial Quality Assurance, reported an automatic share withholding related to equity compensation. On January 18, 2026, 3,390 shares of common stock were withheld by the company at a value of $2.10 per share to cover tax obligations from the vesting and settlement of a restricted stock unit award. After this withholding, she beneficially owned 106,628 shares of Opus Genetics common stock directly. The footnote clarifies this was not an open market sale of securities but a tax-related withholding by the issuer.

Opus Genetics, Inc. officer Amy Zaremba Rabourn, Head of Fin. Quality Assurance, reported a share withholding related to equity compensation. On 01/10/2026, the issuer withheld 3,950 shares of common stock at $1.93 per share to cover tax obligations from the vesting and settlement of a restricted stock unit award. This was not an open market sale of securities, but an administrative tax withholding. After this transaction, Rabourn beneficially owned 110,018 shares of Opus Genetics common stock, held directly.

Opus Genetics, Inc. director Cam Gallagher reported a new equity award and his current share holdings. On January 6, 2026, he received a grant of 67,000 restricted stock units (RSUs) of common stock at a price of $0. These RSUs vest on December 29, 2026, if he continues to provide service through that date.

After this grant, Gallagher beneficially owns 1,991,430 shares of Opus Genetics common stock directly. The filing also notes 83,000 shares held indirectly by him as custodian for a minor child under the Uniform Transfers to Minors Act, and he disclaims beneficial ownership of those shares except to the extent of any pecuniary interest.

Opus Genetics, Inc. (IRD) reported an insider transaction amendment. The Chief Executive Officer and Director filed a Form 4/A clarifying that 30,350 shares of common stock were withheld by the issuer on 11/01/2025 to satisfy tax obligations from an RSU vesting event, coded F (tax withholding). This was not an open‑market sale.

Following the transaction, the reporting person beneficially owned 1,291,654 shares directly. The amendment was filed solely to add a footnote explaining the nature of the transaction.

Opus Genetics (IRD) disclosed an insider transaction by its Chief Executive Officer and Director. On 11/01/2025, a Form 4 reports a transaction coded “F” involving 30,350 shares of common stock at $2.30 per share. After this transaction, the reporting person beneficially owned 1,291,654 shares, held directly.

Opus Genetics (IRD) reported an insider transaction on a Form 4. On 10/22/2025, a transaction in Common Stock with code F involved 23,795 shares at $1.95. After this activity, the reporting person beneficially owns 319,005 shares, held directly.

The reporting person is listed as a Director and Officer (President), and the filing was made by one reporting person.